Saturday 17 October 2026
Export ABSI’s income statement to Excel — free account
Absci Corporation
ABSI Healthcare Biotechnology
Absci Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, down 38.2% from fiscal 2024. In the quarter to June 2026, revenue fell 46.4%, EPS grew 12.5%, free cash flow fell 71.7% and total debt fell 93.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.25
0.63
−7.09%
Follow ABSI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
155.26 | 170.48 | 249.94 | 1,169.18 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(17.46) | (16.36) | (17.44) | (66.21) | |
P/B ratio |
2.08 | 2.52 | 2.67 | 7.42 | |
Price to Tangible BV |
2.60 | 3.23 | 3.50 | 8.86 | |
EV/Sales |
95.78 | 119.28 | 181.73 | 1,040.47 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.34) | (3.59) | (3.43) | (15.03) | |
EV/FCF |
(3.37) | (3.60) | (3.43) | (14.93) | |
Quick Ratio |
5.72 | 6.34 | 6.28 | 10.26 | |
Current Ratio |
5.89 | 6.57 | 6.59 | 10.63 | |
Net Debt/EBITDA |
6.13 | 5.08 | 4.46 | 6.39 | |
Debt/Assets |
0.56% | 0.40% | 0.21% | 0.06% | |
Debt/Equity |
0.01 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF/Net income |
0.87 | 0.99 | 0.89 | 0.83 | |
Capex/Depreciation |
(0.34) | 0.08 | (0.01) | 0.02 | |
Interest Coverage |
(670.09) | (1,070.38) | (1,713.67) | (17,079.00) | |
Research and Development Expense of Revenue |
5,092.33% | 3,899.54% | 8,965.12% | 7,111.95% | |
Selling, General and Administrative Expense of Revenue |
2,233.07% | 1,325.69% | 4,213.02% | 2,881.76% | |
Intangible Assets out of Total Assets |
0.17 | 0.19 | 0.21 | 0.15 | |
Share Based Compensation of Revenue |
1,163.49% | 654.92% | 2,037.21% | 1,648.11% | |
Graham Net Nets |
0.32 | 0.26 | 0.24 | 0.10 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(29.61%) | (24.36%) | (27.67%) | (6.90%) | |
Free Cash Flow Yield |
(18.32%) | (19.42%) | (21.20%) | (5.96%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.17) | (0.21) | (0.17) | (0.17) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.18) | (0.21) | (0.17) | (0.17) | |
Cash per Share |
1.17 | 1.05 | 0.82 | 1.28 | |
Shareholders Equity per Share |
1.46 | 1.39 | 1.12 | 1.56 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.46 | 1.39 | 1.12 | 1.56 | |
Free Cash Flow |
(25.99) | (28.95) | (26.33) | (27.52) | |
Working Capital |
145.29 | 126.81 | 111.94 | 188.67 | |
Capital Expenditures |
(0.96) | 0.23 | (0.03) | 0.04 | |
Net Current Asset Value |
140.34 | 122.73 | 108.35 | 185.48 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
2.55 | (0.36) | 0.12 | (0.13) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.52 | — | — | — | |
Average Payables |
3.13 | 14.90 | 11.13 | 12.23 | |
Average Assets |
240.11 | 214.95 | 214.02 | 239.40 | |
Average Common Equity |
205.84 | 184.29 | 185.38 | 209.75 |
Columns are period end dates